Circulation Journal Official Journal of the Japanese Circulation Society http://www. j-circ.or.jp t is estimated that approximately 5% of patients referred for percutaneous coronary intervention (PCI) have an indication for long-term oral anticoagulation (OAC), mainly because of atrial fibrillation (AF). 1-4 Current guidelines recommend bridging therapy (BT) with unfractionated heparin or low-molecular-weight heparin (LMWH) to cover the temporary discontinuation of OAC, if the risk of thromboembolism is considered high. 5 Neither randomized trials nor large prospective datasets, however, have compared different strategies to manage long-term OAC during PCI. Data from recent observational studies suggest that uninterrupted OAC (UAC) could replace heparin bridging in OAC patients undergoing PCI with favorable balance between bleeding and thrombotic complications. Performing PCI during therapeutic anticoagulation (international normalized ratio [INR] 2.0-3.0) is currently regarded as an alternative strategy. 6,7 Given these prerequisites, we decided to test the hypothesis that UAC would not increase periprocedural bleeding and thrombotic compli-I
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cations in patients with AF who were receiving OAC at the time of PCI and who were prospectively enrolled in the multicenter Management of patients with Atrial Fibrillation undergoing Coronary Artery Stenting (AFCAS) registry.
Methods
AFCAS is an observational, multicenter, prospective registry of patients with AF (paroxysmal, persistent, or permanent) who were referred for PCI. Between December 2006 and February 2010, 963 consecutive patients with AF undergoing PCI were prospectively enrolled in the AFCAS registry at 17 centers in 5 European countries. Because of the observational design of the study, the only exclusion criteria were unwillingness/inability to participate in the study or to give written informed consent. In the present analysis, we focused on patients with long-term OAC (n=529). These patients were treated with combinations ranging from stopping OAC with no BT to UAC plus LMWH with normal therapeutic dosing. The UAC group (n=290) was defined as the patients in whom OAC was continued throughout the hospitalization and to whom no more than bolus heparin was given during PCI. The 161 patients in whom OAC was interrupted before PCI and which was replaced by therapeutic LMWH treatment formed the BT group. Follow-up was performed by means of telephone calls or clinic visits, which were scheduled at 1, 3, 6, and 12 months after PCI. Patients were asked about their clinical outcomes, hospitalizations and medications. Any additional information needed, was obtained by contacting one of the patient's physicians, other health-care professional, or from death certificates. In this report only the data on in-hospital phase and 30-day follow-up are presented. The primary endpoints were major adverse cardiac and cerebrovascular events (MACCE) and bleeding complications at 30 days follow-up after stenting. MACCE was defined as the occurrence of any of the following at 30 days after PCI: death, myocardial infarction, revascularization of the target vessel (emergency or elective coronary artery bypass grafting or repeated PCI), stent thrombosis or stroke. Bleeding complications were classified as major bleeding according to the Thrombolysis In Myocardial Infarction (TIMI) classification and non-major bleeding complications. 8 Stent thrombosis was defined according to Academic Research Consortium Classification as definite and probable. 9 Myocardial infarction was diagnosed when a rise in the myocardial injury marker level was detected together with symptoms suggestive of acute myocardial ischemia. For the diagnosis of myocardial re-infarction, a new rise >50% above the baseline injury marker level was required. Target vessel revascularization was defined as a re-intervention driven by any lesion located in the stented vessel. This study complies with the declaration of Helsinki and was approved by all participating hospitals ethics committees. All patients enrolled in the study provided written informed consent for participation. The AFCAS trial is registered in www.ClinicalTrials.gov, identifier NCT00596570.
Continuous variables are presented as the mean ± SD and study groups were compared using unpaired t-test. Categorical variables are presented as counts and percentages and were compared using the chi-square or Fisher's exact test. In order to identify the independent predictors for bleeding complications and MACCE, first univariate and then multivariate logistic regression was applied. Only the variables significantly associated with dependent variables (P<0.05) on univariate analysis were included in multivariate analysis. For logistic models, age was categorized into 4 classes consisting of the Propensity scores were used to adjust for potential bias in the comparison between non-randomized BT and UAC groups. The propensity score was calculated as the predicted probability that the patient was treated by UAC as opposed to BT using logistic regression. Baseline clinical characteristics and procedural variables with P<0.2 on univariate analysis were included in the backward stepwise logistic regression model ( Tables 1,2 ). The discrimination of propensity score was tested on receiver operating characteristics (ROC) curve. Propensity score was used for risk adjustment as well as for one-to-one propensity score matching. One-to-one propensity score matching between study groups was done between each patient of the UAC and BT groups according to a difference in the propensity score <0.005. Propensity score stratification analysis was not performed because of the small size of the present series. Results of the logistic regression are presented using odds ratios (OR) and their 95% confidence intervals (CI). A 2-sided P<0.05 was required for statistical significance. All data were analyzed using PASW version 18 (IBM SPSS, Chicago, IL, USA) and SAS System for Windows version 9.1 (SAS Institute, Cary, NC, USA).
Results
The baseline clinical characteristics of the study groups are detailed in Table 1 . There were no differences in gender, age or CHADS2-score (cardiac failure, hypertension,age >75, diabetes, prior stroke) between the groups. In the BT group, there were more patients with diabetes and hypertension and the indication for stenting was less often stable angina pectoris. The procedural variables are summarized in Table 2 . Femoral access was more common (P<0.001) in the BT group, while there was no difference in the use of drug-eluting stents between the groups.
In the BT group, OAC was interrupted for a median of 5 days (before PCI, median 3 days). A total of 116 patients (72%) received LMWH ≥4 days. The periprocedural INR was higher in the UAC group (2.3 vs. 1.8, P<0.001). Vitamin K was seldom used to reverse anticoagulation, and mainly in 1 center (9 patients). Only 5 patients (1.7%) in the UAC group and 3 patients (1.9%) in the BT group did not receive periprocedural clopidogrel, and aspirin was started not later than during PCI in almost all patients (BT group, 97.5%; UAC group, 96.6%). Periprocedural heparin bolus (mean dose 4,700 IU) and glycoprotein inhibitors were given more often in the BT group ( Table 3) . Triple therapy of aspirin, clopidogrel plus OAC and/or LMWH was the most often used regimen after PCI in both study groups ( Table 3) .
The length of hospitalization after PCI was longer in the BT group both in elective and in acute patients (3.2±2.9 vs. 1.9±4.6 days and 7.0±10.4 vs. 5.3±6.3 days, respectively; P<0.05 for both). The rates of adverse events during the 30-days post-PCI follow-up in the 2 groups are given in Table 4 . There were no significant differences in the occurrence of MACCE or major bleeding events between the groups. Thromboembolic complications were very rare; only 1 stroke in the UAC group. During the index hospitalization, all bleeding events including also access site complications were more 
Discussion
In the light of the present multicenter prospective study, the simple strategy of UAC is a tempting alternative to BT. The incidence of severe adverse events was similar for both strategies and the excess of minor bleeding and access site complications in the BT group was mainly driven by the common use of the femoral route in these patients.
Recently, the safety and efficacy of BT has been questioned in patients undergoing coronary angiography, pacemaker implantations or pulmonary vein ablation. 10-13 BT offered no advantages in any of these studies and might even have increased bleeding events. 12 Furthermore, heparin bridging prolongs hospitalization, 14,15 and may also contribute to the observations that patients with acute coronary syndromes while on long-term OAC are significantly less likely to undergo coronary angiography and PCI, and waiting times for these procedures are longer in the OAC-treated patients than in those not on OAC. 14 In AF patients on OAC, effective anticoagulation is necessary during PCI not only to avoid thromboembolic complications, but also to avoid thrombotic complications of the intervention. Because warfarin is known to increase activated coagulation time in a predictable fashion, 16 it is reasonable to consider that therapeutic OAC could replace LMWH and be as effective as periprocedural heparin treatment. Performing PCI without interrupting OAC avoids the potential thrombotic risks associated with periods of subtherapeutic anticoagulation if the interruption is not fully covered by LMWH. Also, wide fluctuations in INR are known to be common and long-lasting after interruption leading to prolonged BT. Additionally, warfarin re-initiation may cause a transient prothrombotic state due to protein C and S suppression. 17 The question of whether UAC is associated with a higher risk of bleeding because of difficulties in controlling hemorrhage appears not valid, because rapid reversal of anticoagulation can be obtained using plasma and/or coagulation proteins. The present findings support the view that therapeutic OAC can replace other modes of procedural anticoagulation with a favorable balance between bleeding and thrombotic complications.
In the current literature, there are no randomized trials comparing different strategies to manage long-term OAC during PCI. In the only small randomized study therapeutic OAC and warfarin withdrawal (≥48 h) resulted in similar outcome in patients undergoing coronary angiography, but it took a median of 9 days for INR to return to the therapeutic level. 15 In the earlier non-randomized studies, this simple UAC strategy was at least as safe as that of more complicated interrupted OAC, but the low methodological quality of studies precludes any definitive conclusions. 6 Current guidelines include limited guidance on long-term OAC during the peri-PCI period and some have even ignored 18 In the European Society of Cardiology (ESC) guidelines for the management of valvular heart disease, continuation of OAC at modified doses is recommended for the majority of patients who undergo cardiac catheterization. 19 Arterial puncture is deemed safe when INR remains <2.0, and if a higher INR is needed, the radial approach is recommended. In the American College of Cardiology/American Heart Association guidelines for valvular heart disease, it is recommended that optimal peri-procedural INR should be <1.5 instead. 20 Only in the recent consensus paper of the Working Group on Thrombosis of the ESC, endorsed by the European Heart Rhythm Association and European Association of Percutaneous Cardiovascular Interventions, the UAC strategy is recommended as the preferred strategy for AF patients at moderate to high risk of thromboembolism. 2 In addition to the effective anticoagulation, potent antiplatelet treatment is needed during the peri-procedural period in OAC patients undergoing PCI for effective stent thrombosis prevention. Current guidelines recommend that both aspirin and clopidogrel should be given in the peri-PCI period and continued for at least 1 month after elective implantation of bare metal stents and up to 12 months after implantation of drug-eluting stents and/or in the setting of acute coronary syndromes regardless of the type of stent implanted. 21 Although the shortness of follow-up (ie, 30 days) in the present study precludes solid conclusions, the widespread use of the triple therapy OAC, aspirin and clopidogrel in the vast majority of the present patients may have played a major role in the very low incidence of MACCE in such a vulnerable patient group. Despite the reported high incidence of bleeding complications with triple therapy, in the present subjects the absolute major bleeding rate was lower than in earlier studies. Variability of bleeding definitions may have partly contributed to this finding.
The present study carries all the inherent limitations of prospective non-randomized studies including individual riskbased decision making in the treatment choices. In addition to the differences in the perioperative use of OAC, other differences in the management strategies and patient selection may have modified the present results, all of which may not be covered by propensity and multivariate analyses. Although the most comprehensive so far, the trial was slightly underpowered to cover small, but clinically significant differences in bleeding and thrombotic complications between the 2 strategies. If the rate of all bleeding events was assumed to be 10% for UAC, enrollment of at least 160 patients per group would have yielded >80% power to detect non-inferiority of a strategy for the outcome of bleeding events (1-sided α significance level 0.05). Of note, preoperative INR levels were high in the bridging group, because vitamin K was seldom used in acute patients. In spite of these prerequisites, we feel that the present data may be used to guide the treatment of patients with an indication of long-term OAC undergoing PCI, and would be helpful in planning future prospective studies on this topic.
In conclusion, performing PCI during UAC appears not to be associated with an increase in the risk of bleeding or MACCE when compared to BT. Bleeding events and MACCE are not related to the INR levels. The simple UAC strategy may lead to considerable cost savings compared with conventional BT owing to the significantly reduced length of hospitalization. Finally, the present findings also support the notion that the radial approach is associated with a lower rate of access site complications irrespective of the anticoagulation strategy.
